Jiwon Huh joined Hayan Health Networks, the corporate venture capital (CVC) arm of Boryung Holding, the parent entity of South Korea-based pharmaceutical firm Boryung Pharmaceutical.
The unit, which is based in the US city of San Francisco, makes investments in life sciences and healthcare companies focused on finding innovative treatments for rare, hard-to-treat diseases. It typically participates in early-stage rounds.
Its portfolio includes fibrosis-relate treatment developer Chemomab Therapeutics, antibody discovery platform Rubryc Therapeutics, biotech company 3T Biosciences and adoptive cell therapy company Immpact Bio.
Huh has also worked as director of corporate strategy for Boryung Holding’s pharmaceutical business beginning in March 2019, before which she spent a year in a business development role and as interim project leader at Orum Therapeutics.
Prior to that, she spent two years at Archigen Biotech, a joint venture between pharmaceutical firm AstraZeneca and electronics manufacturer Samsung, as project manager and senior manager for business strategy and planning.
She had also worked six months as senior engineer for quality evaluation at Samsung Bioepsis, and as business development manager for Hanwha Chemical Corporation’s biologics business.
She holds a PhD in biochemistry from Washington University in St. Louis and a BSc in biochemistry from Yonsei University.
